AstraZeneca PLC (AZN)

Hold Current rating · 3 reports

Coverage summary

Aardvark Labs Capital Research has covered AstraZeneca PLC (AZN) since April 30, 2026. The company is in the Healthcare sector. This page lists 3 reports: 3 earnings recaps.

The latest is the Q3 2026 Earnings Recap, published November 1, 2026. That report moved the rating from Outperform to Hold. The rating has changed once since coverage began.

Translations: 2 in Chinese.

Rating history

April 30, 2026 First rating: Outperform Q1 2026 Earnings Recap
November 1, 2026 Outperform → Hold Q3 2026 Earnings Recap

All AZN reports

2026-11-01

Hold Recap: Q3 2026

The Best Operating Quarter of the Year Meets the Cash Trigger We Set in July; Downgrading to Hold

2026-07-28

Outperform Recap: Q2 2026

Four Wins and Three Misses Put the Pipeline on Its Own Assumed Base Rate; a Tax Credit Carries the EPS Beat

2026-04-30

Outperform Recap: Q1 2026

Four Phase III Wins Reset the Pipeline Debate; a Tax Line, Not the Business, Held Core EPS to +5%